Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future Directions
Oncologic disease is a significant global health issue that causes thousands of deaths annually, and it has a significant impact on the quality of life of patients. Prostate cancer (PCa) is the second most diagnosed cancer and the fourth leading cause of cancer-related death in men in the Western wo...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | BioChem |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-6411/3/3/9 |
| _version_ | 1797581209752043520 |
|---|---|
| author | Rafaella S. Coelho Sandra M. Rocha Cláudio J. Maia |
| author_facet | Rafaella S. Coelho Sandra M. Rocha Cláudio J. Maia |
| author_sort | Rafaella S. Coelho |
| collection | DOAJ |
| description | Oncologic disease is a significant global health issue that causes thousands of deaths annually, and it has a significant impact on the quality of life of patients. Prostate cancer (PCa) is the second most diagnosed cancer and the fourth leading cause of cancer-related death in men in the Western world. Delineation of pathogenetic pathways and key driver molecular alterations involved in PCa development has provided a roadmap for the evaluation of biomarkers in predicting disease outcome and to identify potential therapeutic targets. Chemotherapeutic agents introduced from the 1990s include the taxanes (paclitaxel, docetaxel, and cabazitaxel), which are the anticancer drugs used most frequently for PCa treatment. This review presents the current knowledge about the onset and development of PCa, the state of the art of the use of taxane-based therapy, and their combination with targeting different transmembrane oncoproteins in PCa. The silencing of some transmembrane proteins can improve taxane sensitivity, and therefore may be a mechanism to improve the effectiveness of these drugs in PCa treatment. This combined therapy needs to be explored as a potential therapeutic agent for reducing cell proliferation, migration, and invasiveness in PCa. |
| first_indexed | 2024-03-10T23:02:03Z |
| format | Article |
| id | doaj.art-0e51868948544570bea93ffab110018f |
| institution | Directory Open Access Journal |
| issn | 2673-6411 |
| language | English |
| last_indexed | 2024-03-10T23:02:03Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | BioChem |
| spelling | doaj.art-0e51868948544570bea93ffab110018f2023-11-19T09:36:08ZengMDPI AGBioChem2673-64112023-08-013311814110.3390/biochem3030009Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future DirectionsRafaella S. Coelho0Sandra M. Rocha1Cláudio J. Maia2CICS-UBI-Health Sciences Research Center, University of Beira Interior, 6200-506 Covilhã, PortugalCICS-UBI-Health Sciences Research Center, University of Beira Interior, 6200-506 Covilhã, PortugalCICS-UBI-Health Sciences Research Center, University of Beira Interior, 6200-506 Covilhã, PortugalOncologic disease is a significant global health issue that causes thousands of deaths annually, and it has a significant impact on the quality of life of patients. Prostate cancer (PCa) is the second most diagnosed cancer and the fourth leading cause of cancer-related death in men in the Western world. Delineation of pathogenetic pathways and key driver molecular alterations involved in PCa development has provided a roadmap for the evaluation of biomarkers in predicting disease outcome and to identify potential therapeutic targets. Chemotherapeutic agents introduced from the 1990s include the taxanes (paclitaxel, docetaxel, and cabazitaxel), which are the anticancer drugs used most frequently for PCa treatment. This review presents the current knowledge about the onset and development of PCa, the state of the art of the use of taxane-based therapy, and their combination with targeting different transmembrane oncoproteins in PCa. The silencing of some transmembrane proteins can improve taxane sensitivity, and therefore may be a mechanism to improve the effectiveness of these drugs in PCa treatment. This combined therapy needs to be explored as a potential therapeutic agent for reducing cell proliferation, migration, and invasiveness in PCa.https://www.mdpi.com/2673-6411/3/3/9PCataxane-based drugscombination therapytransmembrane proteins |
| spellingShingle | Rafaella S. Coelho Sandra M. Rocha Cláudio J. Maia Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future Directions BioChem PCa taxane-based drugs combination therapy transmembrane proteins |
| title | Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future Directions |
| title_full | Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future Directions |
| title_fullStr | Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future Directions |
| title_full_unstemmed | Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future Directions |
| title_short | Combined Therapies with Taxane-Based Chemotherapeutic Drugs in Prostate Cancer: Novel Insights and Future Directions |
| title_sort | combined therapies with taxane based chemotherapeutic drugs in prostate cancer novel insights and future directions |
| topic | PCa taxane-based drugs combination therapy transmembrane proteins |
| url | https://www.mdpi.com/2673-6411/3/3/9 |
| work_keys_str_mv | AT rafaellascoelho combinedtherapieswithtaxanebasedchemotherapeuticdrugsinprostatecancernovelinsightsandfuturedirections AT sandramrocha combinedtherapieswithtaxanebasedchemotherapeuticdrugsinprostatecancernovelinsightsandfuturedirections AT claudiojmaia combinedtherapieswithtaxanebasedchemotherapeuticdrugsinprostatecancernovelinsightsandfuturedirections |